PR Newswire
09 Sep 2022, 08 GMT+10
SYDNEY, Sept. 9, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, today announced that final data from its phase II study of paxalisib in patients with newly diagnosed glioblastoma will be the subject of an oral presentation at the upcoming annual congress of the European Society for Medical Oncology (ESMO), which will be held in person from 9-13 September 2022 in Paris, France.
The oral presentation will summarise key findings of the completed phase II study of paxalisib in glioblastoma, which was previously the subject of a poster presentation at the American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago, IL, in June 2022. The presentation will provide additional detail on pharmacokinetics and pharmacodynamics. The presentation will be delivered by Professor John de Groot, Division Chief of Neuro-Oncology at the University of California, San Francisco, one of the principal investigators on the study.
ORAL PRESENTATION
Title: Pharmacokinetics and pharmacodynamics of paxalisib in newly diagnosed glioblastoma patients with unmethylated MGMT promoter status: Final phase II study results.
Date: Friday, 9 September
Session: CNS Tumours
Abstract ID: 2800
For More Information, Please Contact:-
In the United States: Joe Green Edison Investor Relations Phone: +1 646-653-7030 | In Australia: Jane Lowe IR Department Phone: +61 411 117 774 |
About Kazia Therapeutics Limited
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an oncology-focused drug development company, based in Sydney, Australia.
Our lead program is paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016, paxalisib commenced recruitment to GBM AGILE, a pivotal study in glioblastoma, in January 2021. Seven additional studies are active in various forms of brain cancer. Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in February 2018, and Fast Track Designation for glioblastoma by the US FDA in August 2020. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for DIPG in August 2020, and for AT/RT in June 2022.
Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumour types and has provided compelling evidence of synergy with immuno-oncology agents. A phase I study commenced recruitment in November 2021.
For more information, please visit www.kaziatherapeutics.com or follow us on Twitter @KaziaTx.
This document was authorized for release to the ASX by James Garner, Chief Executive Officer, Managing Director.
SOURCE Kazia Therapeutics Limited
Get a daily dose of Asia Pacific Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Asia Pacific Star.
More InformationDHAKA, Bangladesh - According to Foreign Minister Dr. AK Abdul Momen, Bangladesh and the United States believe in democracy and ...
Naypyitaw, Myanmar - The Tatmadaw, Myanmar's military, showcased its prowess at the 31st ASEAN Armies Rifle Meet (AARM) held in ...
DHAKA, Bangladesh - The next general election may be rescheduled if the BNP wishes to participate, according to Chief Election ...
KATHMANDU, Nepal - The government has announced plans to hold the Third Investment Summit in Kathmandu on April 21-22 next ...
ISLAMABAD, Pakistan - Anwaar-ul-Haq Kakar, the caretaker prime minister, arrived in Abu Dhabi on Sunday for an official visit to ...
BANGKOK, Thailand: In response to heightened Chinese activity in the South China Sea, the United States and the Philippines have ...
NEW YORK, New York - Retreating bond yields and a higher-then-expected GDP reading for the third quarter boosted U.S. stocks ...
WASHINGTON D.C.: President Joe Biden invoked a Cold War-era act this week to boost investment in U.S. manufacturing of medicines ...
NEW DELHI, India: On November 24, the Economic Times (ET) reported that Tesla is ready to invest up to $2 ...
NEW YORK, New York - U.S. stocks closed in positive territory despite a volatile day Tuesday. Spending much time in ...
WASHINGTON D.C.: On November 24, the U.S. Food and Drug Administration (FDA) recalled three more brands of whole and pre-cut ...
DETROIT, Michigan: US electric vehicle (EV) sales are expected to reach a record of 9% of all passenger vehicles this ...